• The aim of deep vein thrombosis (DVT) diagnostic work-up is to maximize both safety and efficiency.
Essentials
• The aim of deep vein thrombosis (DVT) diagnostic work-up is to maximize both safety and efficiency.
• We explored whether D-dimer is safe and efficient as a stand-alone test to exclude DVT.
• Our findings suggest it is a safe, efficient and simplified diagnostic strategy.
• The safety of age-adjusted D-dimer as a stand-alone test requires further investigation.
Summary. Background: Several strategies for safely excluding deep vein thrombosis (DVT) while limiting the number of imaging tests have been explored. Objectives: To determine whether D-dimer testing could safely and efficiently exclude DVT as a stand-alone test, and evaluate its performance as compared with strategies that incorporate the Wells score and age-adjusted D-dimer. Patients/Methods: We included consecutive outpatients referred with suspected DVT to the Emergency Department at Østfold Hospital, Norway. STA-Liatest D-Di PLUS D-dimer was analyzed for all patients. Patients with a D-dimer level of ≥ 0.5 lg mL À1 were referred for compression ultrasonography (CUS). In patients with a D-dimer level of < 0.5 lg mL À1 , no further testing was performed and anticoagulation was withheld. Patients were followed for 3 months for venous thromboembolism (VTE). Results: Of the 913 included patients, 298 (33%) had a negative D-dimer result. One hundred and seventythree patients (18.9%) were diagnosed with DVT at baseline. One of 298 patients had DVT despite having a negative D-dimer result, resulting in a failure rate of 0.3% (95% confidence interval [CI] 0.1-1.9%). Adding the modified Wells score would have yielded a failure rate of 0.0% (95% CI 0.0-1.8%) while necessitating 87 more CUS examinations. Age-adjusted D-dimer as a standalone test would have necessitated 80 fewer CUS examinations than fixed D-dimer as a stand-alone test, at the
Introduction
Clinical pretest probability evaluation and D-dimer testing have long been the standard initial steps of deep vein thrombosis (DVT) diagnostic work-up [1] . Assessing pretest probability with the support of clinical prediction rules is recommended to guide further testing and to minimize the risk of false-negative D-dimer results among patients with a high pretest probability of having DVT. The most extensively used and validated clinical prediction rule is the Wells score [2] [3] [4] [5] [6] [7] . Originally consisting of nine items, it utilizes elements from patient medical history and physical examination to add or deduct points in order to produce a total score of DVT likelihood [2, 3] , whereby patients are stratified into low-risk (≤ 0 points), moderate-risk (1-2 points) and high-risk (≥ 3 points) groups (Table 1) . High-risk patients are referred for diagnostic compression ultrasonography (CUS) without Ddimer testing, whereas the remaining patients are referred only in the case of a positive D-dimer result. In a later, modified version of the Wells score, another clinical item was added, yielding 1 point for previously documented DVT [4] , and dichotomizing groups into 'DVT unlikely' (< 2 points) and 'DVT likely' (≥ 2 points), whereby the 'DVT likely' group is referred for CUS without D-dimer testing (Table 2) . Despite its extensive validation and wide use in the current diagnostic work-up of DVT, the Wells score has a few limitations. First, it introduces subjectivity into the judgement of whether a competing diagnosis is more likely than DVT [8] , and it may be less precise in certain subgroups, such as in older or primary-care patients [5, 9] . Interobserver variability has not been extensively evaluated [1] . Moreover, D-dimer testing often forms part of a standard package of laboratory tests performed in patients with suspected DVT, and the results may be analyzed before the Wells score in clinically well and lowtriaged patients with suspected DVT in a busy setting in the emergency department. The lack of adherence to clinical prediction rules in daily practice has been addressed in other studies [10, 11] . Finally, the differing prevalences of DVT in various studied populations [4, [12] [13] [14] , perhaps owing to the lower diagnostic threshold seen in recent times [15] , may further affect the utility of clinical prediction rules, such as the Wells score.
The other main component of DVT diagnostic workup is D-dimer testing. Its main advantages include wide availability, a high negative predictive value, and sensitivity for venous thromboembolism (VTE) (97-100% and 93-100% for high-sensitivity assays, respectively) [16] [17] [18] [19] . One disadvantage is the relatively low specificity in certain clinical subgroups, such as older patients [20, 21] . Age-adjusted D-dimer thresholds have been proposed to account for the effect of age on average D-dimer levels [22] . Some studies have reported higher specificity for the diagnosis of DVT when age-adjusted D-dimer is employed, without safety being compromised [23, 24] .
An approach to the diagnostic work-up of DVT that relies on a stand-alone D-dimer test, omitting clinical prediction rules, may be preferable because of its simplicity and ease of standardization, provided that it does not compromise safety.
This management outcome study was aimed at assessing the safety and efficiency of applying fixed D-dimer as a stand-alone test to exclude DVT in an outpatient population. We also conducted post hoc analyses to evaluate and compare the diagnostic performance of fixed and age-adjusted D-dimer thresholds, with and without the Wells score, to find the optimal diagnostic strategy.
Materials and methods

Study population
Outpatients referred to the emergency department of Øst-fold Hospital, Norway are, at the time of writing, being evaluated for enrollment in the Ri-Schedule study (Rivaroxaban In patients with symptoms in both legs, the more symptomatic leg is used. A score of ≥ 2 indicates that the probability of deep vein thrombosis is likely; a score of < 2 indicates that the probability of deep vein thrombosis is unlikely. In patients with symptoms in both legs, the more symptomatic leg is used.
for scheduled work-up of DVT; NCT02486445). It is a single-center prospective outcome study recruiting outpatients with suspected DVT referred from general practitioners to the emergency department. The main goal of the study was to assess the safety of rivaroxaban, administered according to predefined criteria, in the prediagnosis phase of DVT. Among its other aims was the evaluation of D-dimer as a stand-alone test for DVT. This substudy was conducted when approximately half of the patients had been enrolled. The inclusion criteria of the Ri-Schedule study are age ≥ 18 years and referral for first or recurrent clinically suspected lower-extremity DVT. Exclusion criteria are previous inclusion in the Ri-Schedule study within the past 3 months, or inability or unwillingness to provide written consent. Furthermore, patients with expected survival of < 3 months are excluded from the analysis of VTE developing within 3 months.
Additional criteria for eligibility for management with rivaroxaban (maximum of two tablets within 24 h) in the Ri-Schedule study are absence of active cancer, current pregnancy or nursing, or suspicion of active bleeding. However, all patients, whether eligible for treatment with rivaroxaban or not, are managed according to the D-dimer strategy described in this article.
In summary, this substudy consisted of all patients included in the Ri-Schedule study until August 2017, including those who received rivoraxaban while awaiting CUS and those who did not.
Study design
The study was designed as a prospective evaluation of one diagnostic strategy (fixed D-dimer as a stand-alone test), with which five additional strategies were compared retrospectively. These five, summarized in Fig. 1 , included: fixed D-dimer combined with the original, three-category Wells score [3] ; fixed D-dimer combined with the modified, two-category Wells score [4] ; age-adjusted D-dimer as a stand-alone test; age-adjusted D-dimer combined with the original, three-category Wells score; and age-adjusted Ddimer combined with the modified, two-category Wells score.
The Ri-Schedule study was approved by the Regional Committee for Medical and Health Research Ethics, reference number 2014/377. The researchers adhered to the Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects.
Diagnostic procedure
All included patients were evaluated according to the Wells clinical score before the D-dimer results were available. According to the study protocol, the score was obtained for later use in the post hoc analyses of diagnostic performance of the different strategies. The study personnel were instructed to not use it to guide initial management. D-dimer was analyzed with the immunoturbidometric method of STA-Liatest D-Di Plus (Stago Diagnostics, Asnieres, France). A positive fixed D-dimer result was defined as a level of ≥ 0.5 lg mL À1 . Patients with a D-dimer level of < 0.5 lg mL À1 were considered not to have DVT regardless of Wells score, and remained untreated with no further diagnostic tests at baseline. For age-adjusted D-dimer, we used a positivity threshold of ≥ age 9 0.01 lg mL À1 for patients aged ≥ 50 years [22] .
For younger patients, we used a positivity threshold of ≥ 0.5 lg mL
À1
. Patients with positive D-dimer results were referred for whole-leg CUS. All veins were assessed for compressibility. The iliac vein, the femoral veins and the popliteal vein were scanned continuously along their entire length with a linear probe (5-10 MHz) with the patient in a supine position. Axial calf veins were normally scanned with the patient seated. In selected cases, scanning in a prone or standing position was performed. The preferred criterion for DVT was incompressibility [1] . If this was not possible, a gray-scale visualization of the thrombus was accepted. The diagnostic criterion for recurrent DVT was non-compressibility of a venous segment that was previously fully recanalized or that was not initially involved according to the reference CUS.
All patients considered to be DVT-negative according to either negative D-dimer or CUS results were discharged and followed up at 3 months to determine the occurrence of VTE. Patients were advised to seek medical attention if symptoms progressed or persisted, or if they developed other symptoms of DVT or pulmonary embolism. At the end of the follow-up period, all patients received a telephone call from study personnel to establish whether they had been diagnosed with VTE or had been started on anticoagulation for any reason. Patients in whom anticoagulation had been initiated for reasons other than VTE within the 3-month follow-up period were excluded from analyses. Patients with suspected concurrent pulmonary embolism at baseline were managed according to hospital guidelines instead of according to the trial protocol.
Post hoc analyses of different diagnostic strategies
As these analyses were performed after the study had ended, we used the criteria that would have led to a referral for CUS in each strategy, as illustrated in Fig. 1 If the patient did not meet the criteria for CUS as defined by each strategy, we considered that they would not have been referred for CUS, and would have remained without further diagnostic testing or anticoagulation at baseline.
Outcomes
The primary outcome was the failure rate of the primary diagnostic strategy, defined as the proportion of patients either diagnosed with symptomatic VTE or deceased, possibly because of VTE, within 3 months among patients in whom DVT had been ruled out because of a negative Ddimer result and who were left untreated (number of patients diagnosed with VTE at baseline or at 3-month follow-up with a negative D-dimer result/all patients with a negative D-dimer result). Efficiency was expressed as the proportion of patients requiring CUS because of a positive D-dimer result (number of patients with a positive D-dimer result/all included patients).
The secondary outcomes were the failure rate, proportion of required CUS examinations and diagnostic performance of the five additional strategies as compared with the primary strategy. Failure rate was defined as the proportion of patients who did not meet the criteria for undergoing CUS as defined by each strategy (i.e. considered to be DVT-negative), but who were nevertheless diagnosed with VTE either at baseline or during the 3-month follow-up period. The proportion of required CUS examinations was considered to be the proportion of all patients fulfilling the criteria for undergoing CUS according to each strategy. Diagnostic performance was expressed as sensitivity, specificity, negative predictive value, and positive predictive value.
Statistical analysis
The analyses were not planned for in the original protocol of the Ri-Schedule study, but it was later decided to conduct them when 50% of the patients had been enrolled to evaluate the safety and feasibility of ageadjusted D-dimer as a stand-alone test for the rest of the patients in the study. On the basis of previous studies, negative D-dimer results were expected in 23-35% of patients [25] , yielding an estimate of 300 patients in whom DVT was ruled out on the basis of a negative D-dimer result.
A post hoc power calculation showed that a sample size of 306 patients would be needed to detect an incidence rate of < 2% with a power of 80% at a 5% significance level. The failure rates of the different diagnostic strategies with 95% confidence intervals (CIs) were compared with the failure rate of fixed D-dimer as a stand-alone test with a 95% CI. The proportion of CUS examinations yielded by each diagnostic strategy was compared with that of D-dimer as a stand-alone test, all according to absolute differences and with corresponding 95% CIs.
The diagnostic performances of the six strategies were expressed as sensitivity, specificity, positive predictive value and negative predictive value with their respective 95% CIs. Percentages and degree of overlapping of CIs were used to compare strategies.
Diagnostic properties were calculated with OPENEPI statistical software, Version 3.01 (OpenEpi, Atlanta, GA, USA), and Wilson method was used for calculation of binomial 95% CIs.
Results
General findings
The demographic characteristics of the patients are outlined in Table 3 .
Of the 1338 patients screened for participation, 973 were found to be eligible, provided written consent, and were included (Fig. 2 ). Of these, 60 patients received anticoagulation for reasons other than VTE between inclusion and the 3-month follow-up, and were excluded from further analyses, resulting in a total of 913 patients in the final analysis. Fourteen patients were enrolled in the study twice.
Six hundred and fifteen patients (67%, 95% CI 64.3-70.3%) had positive fixed D-dimer results, whereas 298 patients (33%, 95% CI 29.7-35.8%) had negative D-dimer results (Fig. 3) . The proportion of patients with positive fixed D-dimer results and a 'DVT likely' pretest probability was 40% (364 patients). The proportion of patients with positive age-adjusted D-dimer results and a 'Wells likely' pretest probability was 36% (327 patients).
Thirty-six patients were referred for CUS despite having a negative D-dimer result, of whom one was diagnosed with DVT. The reasons for undergoing CUS despite a negative D-dimer result are summarized in Fig. 3 . One hundred and seventy-three patients (18.9%, 95% CI 16.5-21.6%) were diagnosed with DVT at baseline. One hundred and twenty-nine DVTs (75%) were proximal and 44 (25%) were distal.
Study performance and 3-month outcome of D-dimer as a stand-alone test
There were no losses to follow-up or deaths in this group. Table 4 shows the diagnostic performance of the test. One of 298 patients with negative D-dimer results was diagnosed with DVT at baseline. This was one of the 36 patients who underwent CUS at baseline despite a negative D-dimer result. She was in her early fifties and had a 2-day history of calf swelling and pain. Her only established risk factor for DVT was medication with medroxyprogesterone (Depo-Provera), the indication for which was not documented in hospital records. Clinical examination gave normal findings, except for unilateral pitting edema and tenderness along the deep venous system, resulting in a Wells score of 2. She was referred for CUS despite a negative D-dimer result, because of severe pain. CUS revealed incompressibility immediately distal to the bifurcature of the popliteal vein, indicative of a 1-2-cmlong thrombus.
No patients with negative D-dimer results were diagnosed with VTE during the 3-month follow-up.
One of 298 patients with negative D-dimer results who were analyzed had DVT at the 3-month follow-up, yielding a failure rate of 0.3% (95% CI 0.1-1.9%).
Study performance and 3-month outcomes of the various strategies
Patient outcomes and the diagnostic performances of all of the diagnostic strategies are outlined in Table 4 . Addition of the modified Wells score to the fixed D-dimer strategy would have detected the one patient missed by fixed Ddimer as a stand-alone test, but would have necessitated 179 (20) 38 (22) 141 (19) Active cancer within the past 6 months, n (%)
47 (5) 16 (9) 31 (4) Surgery or immobilization for >3 days, n (%)
49 (5) 14 (8) 35 (5) Hormonal contraceptives, n (%)
22 (2) 7 (4) 15 (2) Hormone replacement therapy, n (%)
88 (10) 12 (7) 76 (10) Known thrombophilia, n (%)
28 (3) 9 (5) *In patients with negative diagnostic work-up at baseline. †According to the criteria warranting ultrasonography in each strategy.
distal DVT and three with proximal DVT. Adding the modified Wells score to age-adjusted D-dimer generated a similar safety profile as fixed D-dimer as a standalone test, although necessitating an additional 44 CUS examinations. Two of the strategies had a lower proportion of required CUS examinations than fixed D-dimer as a stand-alone test: age-adjusted D-dimer as a stand-alone test generated 80 fewer CUS examinations (8.8%, 95-% CI À 13.2% to À 4.4%), whereas the negative predictive value was reduced from 99.7% (95% CI 98.1-99.9%) to 98.4% (95% CI 96.6-99.3%).
Adding the original, three-category Wells score yielded 46 fewer CUS examinations (5.1%, 95% CI À 9.5% to À 0.7%) at the cost of a lower negative predictive value, i.e. 98.5% (95% CI 96.6-99.4%).
Adding the Wells score generated more CUS examinations than both D-dimer thresholds as stand-alone tests, and the modified Wells score generated more CUS examinations than the original Wells score. Applying the modified Wells score to the fixed and age-adjusted cut-offs yielded 9.5% (95% CI 5.4-13.6%) and 4.8% (95% CI 0.6-9.0%) more CUS examinations than fixed D-dimer as a stand-alone test, respectively. The negative predictive value increased to 99.6% (95% CI 97.8-99.9%) when the modified Wells score was added to fixed D-dimer, and remained unchanged for age-adjusted D-dimer with the modified Wells score.
Discussion
Safety of fixed D-dimer as a stand-alone test
In this study, we found that D-dimer testing as a standalone test in the diagnostic work-up safely excluded DVT.
To our knowledge, only two other prospective outcome studies have evaluated D-dimer testing as a stand-alone test for excluding VTE [26, 27] , and, as far as we know, ours is the only recent study to do so for DVT. The previous studies found similar overall negative predictive values of 99.3% and 99.8%, respectively. The studies had similar sample sizes, used other D-dimer assays, and had prevalences of VTE of 23% and 12%, respectively, supporting our findings.
In spite of high negative predictive value for D-dimer testing, the safety of D-dimer testing as a stand-alone test for pulmonary embolism is subject to ongoing debate, even when a higher positivity threshold for D-dimer is applied, i.e. 750 lg L À1 , than used in our study [28] .
The failure rate of 0.3% (95% CI 0.1-1.9%) of fixed D-dimer as a stand-alone test corresponds to the failure rates yielded by negative CUS results, ranging between 0.57% and 2.0%, with 95% CIs ranging from lower to upper limits of 0.2% to 5.1% [29, 30] . Moreover, it compares favorably with the failure rate after a negative venography result (1.3%) [31] , which is the reference standard for DVT diagnostic tests or algorithms [1] . Finally, the upper limit of the CI of the post-test probability of DVT for fixed D-dimer as a stand-alone test was < 2%. This is considered to be a satisfactory degree of certainty in diagnostic testing for withholding treatment [1] .
Comparison of fixed D-dimer as a stand-alone test with other strategies
Regarding our secondary outcome measures, we found that fixed D-dimer as a stand-alone test was equally safe as established diagnostic strategies incorporating the Wells score in the algorithm. Furthermore, of the two strategies with an upper 95% CI failure rate limit of ≤ 2%, fixed D-dimer as a stand-alone test generated the fewest number of CUS examinations.
Early published evaluations of combined Wells score and D-dimer strategies found similar failure rates as described in our study (0.4% [95% CI 0.05-1.5%] and 0.6% [95% CI 0.1-1.8%]) [3, 4] . The Wells score has subsequently been extensively validated and clinically employed, spanning at least 14 studies with > 10 000 patients [32] .
Age-adjusted D-dimer as a stand-alone test had the highest specificity and resulted in the fewest CUS examinations of all strategies. However, it was associated with lowered sensitivity and an additional five false-negative cases, of whom three had proximal thrombi, as compared with fixed D-dimer as a stand-alone test. Given that the analysis was conducted retrospectively, the clinical significance of missing these thrombi is uncertain.
Prospective outcome studies to explore the safety of age-adjusted D-dimer as a stand-alone test are needed before its use in clinical practice can be considered. Current prospective studies validating age-adjusted D-dimer may help to guide future diagnostic work-up of DVT (NCT02384135).
Strengths and limitations
The strengths of our study include its prospective outcome design and collection of data, standardized assessment, including the same D-dimer assay in all patients, and no losses to follow-up in the group with negative D-dimer results who did not undergo CUS. Additionally, the DVT prevalence of 19% in our study is comparable to that in other similarly designed diagnostic studies [3, 4, 26, 27] . This relatively high prevalence decreases the likelihood of a low failure rate resulting from a low prevalence, which may arise as a result of the lower diagnostic threshold seen in recent times [15] .
A limitation of our single-center study is possibly weaker generalizability than a multicenter study would yield. Another limitation is the protocol deviations whereby patients did and did not undergo CUS despite negative and positive D-dimer results, respectively. These deviations would probably continue to exist in the case of implementation of D-dimer as a stand-alone test, as there would be a need to clarify other conditions, or to evaluate the extent of clinically suspected thrombophlebitis; also, clinicians may, for other reasons, wish to exclude DVT despite a negative D-dimer result or clinical prediction rules. Of the 36 patients who underwent CUS despite a negative D-dimer result, one was diagnosed with DVT, whose 2-cm-long distal thrombus might have resolved spontaneously. The clinical course and optimal management of distal thrombi are subject to ongoing debate [33, 34] . Furthermore, as analyses for five of the strategies were conducted retrospectively, the clinical significance of the thrombi missed by age-adjusted D-dimer but not by fixed D-dimer remain theoretical. Therefore, our conclusion that the safety of age-adjusted D-dimer as a standalone test is uncertain could only be verified or falsified through prospective outcome studies.
Earlier enrollment in the study was not an exclusion criterion so long as the previous inclusion occurred > 3 months previously. As the patients who were enrolled twice were few in number (14) , and only two were not managed per protocol (one patient did not undergo CUS despite a positive D-dimer result, and one patient underwent CUS despite a negative D-dimer result), we believe that the potential resulting bias is limited. Despite the potential benefits of including patients repeatedly, such as the ability to establish recurrence rates and explore mechanisms of recurrent DVT, the lack of independence between these observations could limit testing for statistically significant differences between strategies.
Although our findings are likely to be generalizable to other outpatient populations with similar DVT prevalences, this may not be the case for inpatient settings or in populations with markedly higher DVT prevalences. Although D-dimer was analyzed with only one method, other studies have documented similar negative predictive values for highsensitivity assays [19] . We therefore believe that our D-dimer results can be extrapolated to these assays.
It is also worth noting that, although patients at high risk for DVT were not excluded from the study, their contribution to the total patient number was limited. For instance, only 5% had cancer, 5% had undergone surgery within the 12 weeks preceding admission, and 0.8% were pregnant. Although none of these patients had false-negative D-dimer results, the numbers of patients in the subgroups were too small to enable conclusions to be drawn regarding the safety of D-dimer testing as a stand-alone test in these groups. Consequently, the results of our study do not warrant changing existing diagnostic evaluation of these patients.
In summary, D-dimer testing as a stand-alone test was found to be equally safe as and to generate fewer CUS examinations than D-dimer testing combined with the Wells score. As the strategy has the additional advantage of being easily adhered to in clinical practice while avoiding subjectivity in evaluation, we believe that it is a preferred approach to simplify the diagnostic work-up of DVT.
Conclusion
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